Investment Rating - The investment rating for Wuxi Jinghai is maintained at "Outperform" [1][2] Core Views - The company reported a revenue of 203 million yuan in H1 2025, representing a year-on-year growth of 18.67%, and a net profit attributable to shareholders of 37.30 million yuan, up 34.77% year-on-year [2] - The company is actively expanding its overseas market share and has established a wholly-owned subsidiary in Singapore, with plans to set up subsidiaries in the Netherlands and the United States [3] - The company is focusing on technological upgrades and has initiated research on high-purity amino acid production technologies, which are expected to enhance its competitive edge in the amino acid market [3] Financial Summary - The total market capitalization of the company is 21.12 billion yuan, with a circulating market capitalization of 9.68 billion yuan [1] - The company's revenue is projected to grow from 402 million yuan in 2025 to 607 million yuan in 2027, with corresponding net profits expected to rise from 73 million yuan to 103 million yuan during the same period [4][6] - The company's earnings per share (EPS) are forecasted to increase from 0.94 yuan in 2025 to 1.32 yuan in 2027, with a price-to-earnings (P/E) ratio decreasing from 29.0 to 20.6 over the same period [4][6]
无锡晶海（836547）：北交所信息更新：氨基酸原料药新锐技术升级，全球化布局焕发新动能升